Think of this as the AVXL MOA patent. This is a broad departure from the meds of the past-site-disease specific. IMO, this gets at the CNS (system) , which is the path we are on, unlike competitors and which has frequently been pointed to by Dr. M. and team . IMO, this is a pointer to the new (next 20+ yrs)...medical serial thinking process. (others here more qualified to carry the concepts ref; Falconer for example) . I do recognize a systems message when I see one and this is a massive headlines to BP serial thinking ...say BAAH...BYE Boys.
My guess is Dr..M. has presented and will prove by AI-Vis-other strong evidence w/trial data to close the lid on past Bio-Med-Pharma old school thinking. He just threw a blanket over BioMed futures. The good news is, they still do not get it, All they can hope for is some kind of multiple partnerships w/AVXL going fwd...IMO.
This kind of PAT approval. is as much about BP-product-structure and portfolio obsolescence as it is about the controls going forward. Listen for the GIANT .."OHHH SHAT"...themes going fwd.